Viral Vectors
Technologies
Gene Therapy & Vaccination
Partners
About us

Seite wählen

Home / About us / Newsroom

Newsroom

If you like to receive our Newsletter directly by email, please subscribe here.

Newsletter
Press Releases
News of Interest
Media Coverage
Investor News

Management
FAQ
Company
References
Newsroom
Investors
Careers
Contact us

contact us

Contact us

Whether you seek help customizing a vector for academic use or support for your industrial R&D, we will assist you from square one to discuss and plan your project in detail.

News

SIRION Biotech Expands US Presence in Massachusetts Europe’s Leading Commercial Provider of Viral Vector Technology Opens Local Office in Cambridge CAMBRIDGE, Mass.--(BUSINESS WIRE)--SIRION Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech GmbH in Germany (“SIRION”), offering the most comprehensive portfolio of custom viral vectors for preclinical and clinical studies, today announced the grand opening of a new office... Learn More

Meet us at

Feb 26-27 LAUSANNE, Switzerland

NVGCT Spring Symposium

Mar 6-8 LUNTEREN, Netherlands

Cell and Gene Therapy Manufacturing Workshop

Mar 11-12 LONDON, UK

SFTCG Thematic days on viral vectors

May 17 PARIS, France

Follow us

Google
Facebook
Twitter
Linkedin

Newsletter

SIRION Biotech’s Viral Vector Technologies for every application, from gene therapy and vaccination development to customization of cell modeling tools.

Viral Vectors
Technologies
Gene Therapy & Vaccination
Partners
About us
- About us
- Contact us
- Company
- Management
- Newsroom
- References
- FAQ
- Careers
- Investors
- Terms
- Legal / Impressum
- Privacy Statement

© Sirion-Biotech GmbH 2019

Terms
Legal / Impressum
Privacy Statement

Please click here to opt-out google analytics

We use cookies. - OK -Learn more -